Immutep (IMMP) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Immutep (IMMPResearch Report) yesterday and set a price target of $8.00. The company’s shares closed last Monday at $2.67.

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -38.8% and a 12.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Immutep is a Moderate Buy with an average price target of $8.00.

See today’s best-performing stocks on TipRanks >>

Immutep’s market cap is currently $251.7M and has a P/E ratio of -10.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Read More on IMMP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed